188 related articles for article (PubMed ID: 29900015)
41. Validation of a scoring system to establish the probability of myelodysplastic syndrome in patients with unexplained cytopenias or macrocytosis.
Rauw J; Wells RA; Chesney A; Reis M; Zhang L; Buckstein R
Leuk Res; 2011 Oct; 35(10):1335-8. PubMed ID: 21704372
[TBL] [Abstract][Full Text] [Related]
42. Hypoxia-inducible factor-1α expression indicates poor prognosis in myelodysplastic syndromes.
Tong H; Hu C; Zhuang Z; Wang L; Jin J
Leuk Lymphoma; 2012 Dec; 53(12):2412-8. PubMed ID: 22632108
[TBL] [Abstract][Full Text] [Related]
43. Evolving treatment options of myelodysplastic syndromes.
Verbeek W; Ganser A
Ann Hematol; 2001 Sep; 80(9):499-509. PubMed ID: 11669297
[TBL] [Abstract][Full Text] [Related]
44. Clinical and genetic predictors of prognosis in myelodysplastic syndromes.
Bejar R
Haematologica; 2014 Jun; 99(6):956-64. PubMed ID: 24881041
[TBL] [Abstract][Full Text] [Related]
45. Alterations of the expression of TET2 and DNA 5-hmC predict poor prognosis in Myelodysplastic Neoplasms.
Seethy AA; Pethusamy K; Kushwaha T; Kumar G; Talukdar J; Chaubey R; Sundaram UD; Mahapatra M; Saxena R; Dhar R; Inampudi KK; Karmakar S
BMC Cancer; 2023 Oct; 23(1):1035. PubMed ID: 37884893
[TBL] [Abstract][Full Text] [Related]
46. Dysfunctional bone marrow endothelial progenitor cells are involved in patients with myelodysplastic syndromes.
Xing T; Lyu ZS; Duan CW; Zhao HY; Tang SQ; Wen Q; Zhang YY; Lv M; Wang Y; Xu LP; Zhang XH; Huang XJ; Kong Y
J Transl Med; 2022 Mar; 20(1):144. PubMed ID: 35351133
[TBL] [Abstract][Full Text] [Related]
47. Myeloid Clonal Infiltrate Identified With Next-Generation Sequencing in Skin Lesions Associated With Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: A Case Series.
Martin de Frémont G; Hirsch P; Gimenez de Mestral S; Moguelet P; Ditchi Y; Emile JF; Senet P; Georgin-Lavialle S; Hanslik T; Maurier F; Adedjouma A; Abisror N; Mahevas T; Malard F; Adès L; Fenaux P; Fain O; Chasset F; Mekinian A
Front Immunol; 2021; 12():715053. PubMed ID: 34671345
[TBL] [Abstract][Full Text] [Related]
48. [Myelodysplastic syndromes].
Solary E; Fontenay M
Rev Prat; 2010 Dec; 60(10):1408-9, 1412. PubMed ID: 21425540
[TBL] [Abstract][Full Text] [Related]
49. Immunosuppressive therapy for myelodysplastic syndromes.
Dobbelstein C; Ganser A
Curr Pharm Des; 2012; 18(22):3184-9. PubMed ID: 22571697
[TBL] [Abstract][Full Text] [Related]
50. Myelodysplastic Syndromes with Bone Marrow Fibrosis: An Update.
Jain AG; Zhang L; Bennett JM; Komrokji R
Ann Lab Med; 2022 May; 42(3):299-305. PubMed ID: 34907099
[TBL] [Abstract][Full Text] [Related]
51. Treatment strategies and issues in low/intermediate-1-risk myelodysplastic syndrome (MDS) patients.
Bowen DT
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S16-23. PubMed ID: 16085013
[TBL] [Abstract][Full Text] [Related]
52. The current approach to the diagnosis of myelodysplastic syndromes
Weinberg OK; Hasserjian RP
Semin Hematol; 2019 Jan; 56(1):15-21. PubMed ID: 30573039
[TBL] [Abstract][Full Text] [Related]
53. The level of bone marrow WT1 message is a useful marker to differentiate myelodysplastic syndromes with low blast percentage from cytopenia due to other reasons.
Baba M; Hata T; Tsushima H; Mori S; Sasaki D; Turuta K; Hasegawa H; Ando K; Sawayama Y; Imanishi D; Taguchi J; Yanagihara K; Tomonaga M; Kamihira S; Miyazaki Y
Intern Med; 2015; 54(5):445-51. PubMed ID: 25758068
[TBL] [Abstract][Full Text] [Related]
54. A systematic modeling study on the pathogenic role of p38 MAPK activation in myelodysplastic syndromes.
Peng H; Wen J; Zhang L; Li H; Chang CC; Zu Y; Zhou X
Mol Biosyst; 2012 Apr; 8(4):1366-74. PubMed ID: 22327869
[TBL] [Abstract][Full Text] [Related]
55. Myelodysplastic syndromes: molecular pathogenesis and genomic changes.
Nolte F; Hofmann WK
Ann Hematol; 2008 Oct; 87(10):777-95. PubMed ID: 18516602
[TBL] [Abstract][Full Text] [Related]
56. [Management of myelodysplastic syndromes in 2019: An update].
Comont T; Delavigne K; Cougoul P; Bertoli S; Delabesse E; Fenaux P; Beyne-Rauzy O
Rev Med Interne; 2019 Sep; 40(9):581-589. PubMed ID: 31054780
[TBL] [Abstract][Full Text] [Related]
57. Biology and clinical management of hypoplastic MDS: MDS as a bone marrow failure syndrome.
Karantanos T; DeZern AE
Best Pract Res Clin Haematol; 2021 Jun; 34(2):101280. PubMed ID: 34404534
[TBL] [Abstract][Full Text] [Related]
58. Apoptosis and prognostic factors in myelodysplastic syndromes.
Shimazaki K; Ohshima K; Suzumiya J; Kawasaki C; Kikuchi M
Leuk Lymphoma; 2002 Feb; 43(2):257-60. PubMed ID: 11999555
[TBL] [Abstract][Full Text] [Related]
59. CXCL12+ stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes.
Abe-Suzuki S; Kurata M; Abe S; Onishi I; Kirimura S; Nashimoto M; Murayama T; Hidaka M; Kitagawa M
Lab Invest; 2014 Nov; 94(11):1212-23. PubMed ID: 25199050
[TBL] [Abstract][Full Text] [Related]
60. The presence of clonal cell subpopulations in peripheral blood and bone marrow of patients with refractory cytopenia with multilineage dysplasia but not in patients with refractory anemia may reflect a multistep pathogenesis of myelodysplasia.
Cermák J; Belicková M; Krejcová H; Michalová K; Zilovcová S; Zemanová Z; Brezinová J; Sieglová Z
Leuk Res; 2005 Apr; 29(4):371-9. PubMed ID: 15725470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
